Abstract

Introduction: Breast cancer is the most common cancer found in women and is one of the diseases associated with aging. Previos studies have found a significant association between the BsmI vitamin D receptor and breast cancer. This study aims to prove the relationship between BsmI vitamin D receptor polymorphisms with clinicopathological features of breast cancer at Sanglah Hospital, Denpasar Bali. Methods: This research is an analytic study with cross sectional method. The samples used in this study were 50 stored biological materials in the form of DNA from breast cancer patients in 2016- 2018 which is in the Biochemistry Laboratory of the Udayana Faculty of Medicine. To determine the polymorphism of the BsmI vitamin D receptor gene, DNA samples from breast cancer patients were amplified by polymerase chain reaction (PCR) method, then identified by sequencing method. The results obtained were then analyzed statistically using bivariate and multivariate analysis by using spss 25.sav. Results: 45 people (90.0%) were found with heterozygous polymorphism G/A and 5 people (10.0%) with homozygous wildtype GG. There was a statistically significant relationship between BsmI vitamin D receptor polymorphism and breast cancer stage at Sanglah Hospital Denpasar Bali (p=0.048). There was no significant relationship between age and history of contraceptive use and clinicopathology of breast cancer, but menstrual status was significant with the stage of breast cancer patients (p=0.037). Conclusion: There is a significant relationship between BsmI vitamin D receptor polymorphism and breast cancer stage at Sanglah Hospital Denpasar Bali.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.